Graham A. Colditz, MD, DrPH | Institute ...

Dr. Graham Colditz, M.D., DrPH

Claim this profile

Washington University School of Medicine

Studies Endometrial Hyperplasia
Studies Colorectal Cancer
5 reported clinical trials
8 drugs studied

Affiliated Hospitals

Image of trial facility.

Washington University School Of Medicine

Clinical Trials Graham Colditz, M.D., DrPH is currently running

Image of trial facility.

Behavioral Weight Loss + Progestin

for Endometrial Hyperplasia

Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal women has resulted in increasing rates of AEH in this age group. Hysterectomy with removal of the fallopian tubes and ovaries is 100% effective in preventing endometrial cancer, but this approach results in infertility. Fertility-sparing treatments exist, such as treatment with oral or intrauterine progestin, but these treatments do not work uniformly and do not combat the underlying cause of endometrial cancer, which is obesity and metabolic syndrome. Additionally, up to 41% of women on progestin eventually experience relapse of AEH or endometrial cancer. Third, many patients have insulin resistance that may worsen with progestin therapy. Thus, to improve treatment of AEH and grade 1 endometrial cancer, prevent and reverse endometrial cancer, and allow women to preserve their fertility, the investigators must integrate an effective weight loss strategy to be given with progestin treatment. It is the hypothesis that premenopausal women with AEH desire uterine preservation will be more likely to have atypia-free uterine preservation at one year if they receive progestin in combination with a behavioral weight loss intervention versus progestin plus enhanced usual care.

Recruiting

1 award

Phase 2

Image of trial facility.

Genetic Results Return

for Cancer Patients

The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding returning of genomic results on participants' health and satisfaction. Participants in this study will be presented with the choice of types of genomic results to receive, and the Engagement Optimization Unit (EOU) will investigate the impact of this intervention on participant knowledge, expectations of benefit, personal utility, and decisional conflict.

Recruiting

1 award

N/A

More about Graham Colditz, M.D., DrPH

Clinical Trial Related

6 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Graham Colditz, M.D., DrPH has experience with

  • Progestin
  • Participant Engagement And Genomic Result Return
  • Denosumab
  • Colorectal Cancer Toolkit
  • Semaglutide
  • Telemedicine Behavioral Weight Intervention

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Graham Colditz, M.D., DrPH specialize in?

Is Graham Colditz, M.D., DrPH currently recruiting for clinical trials?

Are there any treatments that Graham Colditz, M.D., DrPH has studied deeply?

What is the best way to schedule an appointment with Graham Colditz, M.D., DrPH?

What is the office address of Graham Colditz, M.D., DrPH?

Is there any support for travel costs?